[Form 4/A] Astera Labs, Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Astera Labs insider amendment reports multiple disposals and gifts of common stock by Michael Truett Tate, the companys CFO and trustee of the Tate Trust. The Form 4/A shows sales on 08/07/2025 and 08/08/2025: reported disposals include 43,184, 7,550, 15,141, and 34,125 shares sold at weighted-average prices ranging roughly from $169.05 to $174.04. The filing also records two bona fide gifts of 7,500 and 10,000 shares to non-affiliated recipients. Following the reported transactions the filing shows 501,496 shares beneficially owned indirectly by the Tate Trust. The amendment clarifies that a previously reported acquisition by GlobalStar Donor Advised Fund was an administrative error and that the Reporting Person has no pecuniary interest in that fund.

Positive

• Amendment corrected a prior reporting error regarding GlobalStar Donor Advised Fund, improving disclosure accuracy
• Detailed footnotes provide weighted-average price ranges and offer to supply per-trade breakdowns, enhancing transparency
• Gifts reported as bona fide to non-affiliated recipients, with explicit disclosure of nature of transfers

Negative

• Material insider sales totaling 100,000 shares on 08/07/2025 at prices roughly $169$174, which may be viewed negatively by some investors
• Significant reduction in beneficial ownership to 501,496 shares indirectly held by the Tate Trust after transactions

Insights

Financial Analyst

TL;DR: CFO executed sizable open-market sales and gifts; amendment corrects a prior reporting error.

The filing documents open-market disposals totaling 100,000 shares sold across multiple transactions on 08/07/2025 at weighted-average prices in the approximately $169$174 range, plus gifts of 7,500 and 10,000 shares to non-affiliated recipients. The shares remain reported as indirectly owned via the Tate 1997 Living Trust, with 501,496 shares retained post-transactions. From a market-impact perspective, the sales are material on a transaction basis but the filing does not include company financials or context for the disposals, limiting conclusions about motive or valuation impact.

Corporate Governance Expert

TL;DR: Amendment improves disclosure accuracy; gifts and sales were reported with required detail.

The Form 4/A corrects an earlier misreport of a 7,500-share acquisition by a donor-advised fund, clarifying the Reporting Person has no pecuniary interest in that fund. The filing identifies the Reporting Person as CFO and trustee of the Tate Trust and discloses indirect ownership and nature of gifts, which aligns with Section 16 reporting expectations. The amendment and footnotes provide transaction ranges and an offer to supply per-price breakdowns, supporting transparency for compliance review.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tate Michael Truett

(Last) (First) (Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE CA 95131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/11/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2025		S		43,184	D	$169.608(1)	575,812	I	By Tate Trust(2)
Common Stock	08/07/2025		S		7,550	D	$170.3396(3)	568,262	I	By Tate Trust(2)
Common Stock	08/07/2025		S		15,141	D	$171.4778(4)	553,121	I	By Tate Trust(2)
Common Stock	08/07/2025		S		34,125	D	$173.8234(5)	518,996	I	By Tate Trust(2)
Common Stock	08/07/2025		G(6)		7,500	D	$0	511,496	I	By Tate Trust(2)
Common Stock	08/08/2025		G(7)		10,000	D	$0	501,496	I	By Tate Trust(2)
Common Stock								278,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.0500 to $169.9900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.0500 to $170.8600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.0800 to $171.8500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.5950 to $174.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. Represents a bona fide gift of shares to a non-affiliated entity.

7. Represents a bona fide gift of shares to a non-affiliated person.

Remarks:

This Form 4/A (this "Amendment") amends and restates in its entirety the original Form 4 filed with the U.S. Securities and Exchange Commission on August 11, 2025 (the "Original Form") to remove the transaction relating to the acquisition of Astera Labs, Inc. common stock ("Common Stock") by GlobalStar Donor Advised Fund ("DAF"), of which the Reporting Person was inadvertently reported due to administrative error as being a trustee. In fact, the Reporting Person has no pecuniary interest in GlobalStar DAF; as such, the 7,500 shares were gifted to and acquired by a non-affiliated entity, as reported in this Amendment.

	/s/ Philip Mazzara, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did ALAB CFO Michael Truett Tate report on the Form 4/A?

The filing reports sales of 43,184, 7,550, 15,141, and 34,125 shares on 08/07/2025 and a sale of 278,373 shares line item; it also reports gifts of 7,500 and 10,000 shares to non-affiliated recipients and shows 501,496 shares beneficially owned indirectly.

At what prices were the ALAB shares sold in the reported transactions?

Sales on 08/07/2025 occurred at weighted-average prices within ranges reported in footnotes: approximately $169.05$174.04 per share across the separate sale blocks.

What did the amendment (Form 4/A) correct about the original filing?

The amendment removes a mistakenly reported acquisition by GlobalStar Donor Advised Fund, clarifying the Reporting Person is not a trustee of that fund and has no pecuniary interest in it.

How many shares does the Tate Trust beneficially own after the reported transactions?

The filing reports 501,496 shares beneficially owned indirectly by the Tate 1997 Living Trust following the reported transactions.

Were any transactions gifts rather than sales?

Yes. The Form 4/A reports two bona fide gifts: 7,500 shares to a non-affiliated entity and 10,000 shares to a non-affiliated person.